WestCentralOnline·2 min read·medium
Saskatchewan expands Cystic Fibrosis drug coverage with new treatment option
✦AI Summary
The province of Saskatchewan has expanded its public drug coverage to include Alyftrek, a treatment for patients aged six and older with cystic fibrosis. This move follows federal recommendations and pricing negotiations, increasing the number of available therapies for the disease in the region.
People living with cystic fibrosis in Saskatchewan now have access to an additional treatment option as the province begins covering the cost of a new medication.
healthpolitics
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in